{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:29:30Z","timestamp":1787030970513,"version":"build-2736575974"},"reference-count":40,"publisher":"Scientific Scholar","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Approximately three per cent of the world's population (170-200 million people) is chronically infected with hepatitis C virus (HCV) and almost 500,000 people die each year (mostly in lower middle-income countries) from complications secondary to HCV infection. In India, HCV infection imposes a considerable burden of mortality, morbidity and healthcare costs. In the last two decades, the treatment of HCV has evolved from interferon (IFN)-based therapies with or without ribavirin (RBV) to pegylated-IFN (PEG-IFN) and RBV-based therapies that were better tolerated by patients. However, the introduction of oral drugs, which specifically target virus-specific proteins, has now revolutionized the treatment of chronic HCV. These agents are known as direct-acting antivirals (DAAs). These drugs have resulted in very high HCV cure rates even with reduced treatment duration and an excellent tolerability by the patients compared to PEG-IFN- and RBV-based therapies. In India, sofosbuvir (SOF), one of the most effective DAAs, has been made available at a compassionate price; thus only those DAA-based management strategies, which contain SOF are adopted in India. Here, we review different DAAs and their possible roles in different genotypes and stages of liver disease, stressing upon the role of SOF. An attempt has also been made to devise strategies using SOF for the most prevalent genotypes in our country (genotypes 3 and 1) and cirrhosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmr.ijmr_679_15","type":"journal-article","created":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T05:26:35Z","timestamp":1511328395000},"page":"23-33","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Newer direct-acting antivirals for hepatitis C virus infection"],"prefix":"10.25259","volume":"146","author":[{"given":"Varun","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","reference":[{"key":"R1-6-20241212","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/hep.27718","article-title":"A glass half full: Implications of screening for hepatitis C virus in the era of highly effective antiviral therapy","volume":"61","author":"Lutchman","year":"2015","journal-title":"Hepatology"},{"key":"R4-6-20241212","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jceh.2015.09.002","article-title":"Indian National Association for Study of the Liver (INASL) guidance for antiviral therapy against HCV infection in 2015","volume":"5","author":"Puri","year":"2015","journal-title":"J Clin Exp Hepatol"},{"key":"R5-6-20241212","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"Lavanchy","year":"2009","journal-title":"Liver Int"},{"key":"R6-6-20241212","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano","year":"2012","journal-title":"Lancet"},{"key":"R7-6-20241212","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jceh.2014.05.006","article-title":"Consensus statement of HCV task force of the Indian National Association for Study of the Liver (INASL). Part I: Status report of HCV infection in India","volume":"4","author":"Puri","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"R8-6-20241212","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/hep.27365","article-title":"Late diagnosis of hepatitis C virus infection in the Chronic Hepatitis Cohort Study (CHeCS): Missed opportunities for intervention","volume":"61","author":"Moorman","year":"2015","journal-title":"Hepatology"},{"key":"R9-6-20241212","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jceh.2015.05.001","article-title":"Most patients of hepatitis C virus infection in India present late for interferon-based antiviral treatment: An epidemiological study of 777 patients from a North Indian tertiary care center","volume":"5","author":"Gupta","year":"2015","journal-title":"J Clin Exp Hepatol"},{"key":"R10-6-20241212","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/bmb\/ldv004","article-title":"Revolution in hepatitis C antiviral therapy","volume":"113","author":"Sadler","year":"2015","journal-title":"Br Med Bull"},{"key":"R11-6-20241212","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1038\/sj.onc.1209562","article-title":"Viral hepatitis and liver cancer: The case of hepatitis C","volume":"25","author":"Levrero","year":"2006","journal-title":"Oncogene"},{"key":"R12-6-20241212","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: An update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"R13-6-20241212","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R14-6-20241212","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jceh.2014.08.004","article-title":"Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: A study from north India","volume":"4","author":"Gupta","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"R15-6-20241212","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1128\/AAC.00399-10","article-title":"PSI-7851, a pronucleotide of beta-D-2\u2019-deoxy-2\u2019-fluoro-2\u2019-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication","volume":"54","author":"Lam","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R16-6-20241212","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","article-title":"Sofosbuvir for previously untreated chronic hepatitis C infection","volume":"368","author":"Lawitz","year":"2013","journal-title":"N Engl J Med"},{"key":"R17-6-20241212","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","article-title":"Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"384","author":"Jacobson","year":"2014","journal-title":"Lancet"},{"key":"R18-6-20241212","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","article-title":"Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"384","author":"Manns","year":"2014","journal-title":"Lancet"},{"key":"R19-6-20241212","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1053\/j.gastro.2014.02.051","article-title":"Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: A phase 3 trial","volume":"146","author":"Forns","year":"2014","journal-title":"Gastroenterology"},{"key":"R20-6-20241212","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2013.10.058","article-title":"Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial","volume":"146","author":"Zeuzem","year":"2014","journal-title":"Gastroenterology"},{"key":"R21-6-20241212","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R22-6-20241212","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R23-6-20241212","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","article-title":"Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis","volume":"370","author":"Kowdley","year":"2014","journal-title":"N Engl J Med"},{"key":"R24-6-20241212","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"R25-6-20241212","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450\/r-ombitasvir and dasabuvir with ribavirin","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"R26-6-20241212","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","article-title":"Global distribution and prevalence of hepatitis C virus genotypes","volume":"61","author":"Messina","year":"2015","journal-title":"Hepatology"},{"key":"R27-6-20241212","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1208953","article-title":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C","volume":"368","author":"Gane","year":"2013","journal-title":"N Engl J Med"},{"key":"R28-6-20241212","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","article-title":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options","volume":"368","author":"Jacobson","year":"2013","journal-title":"N Engl J Med"},{"key":"R29-6-20241212","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"R30-6-20241212","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/hep.27567","article-title":"Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis","volume":"61","author":"Lawitz","year":"2015","journal-title":"Hepatology"},{"key":"R31-6-20241212","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"R32-6-20241212","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","article-title":"Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study","volume":"384","author":"Lawitz","year":"2014","journal-title":"Lancet"},{"key":"R33-6-20241212","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"R34-6-20241212","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/liv.12576","article-title":"Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: A meta-analysis","volume":"35","author":"Akhtar","year":"2015","journal-title":"Liver Int"},{"key":"R35-6-20241212","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0168-8278(14)60008-8","article-title":"O6 Sofosbuvir\/ledipasvir fixed dose combination is safe and effective in difficult-to-treat populations including genotype-3 patients, decompensated genotype-1 patients, and genotype-1 patients with prior sofosbuvir treatment experience","volume":"60","author":"Gane","year":"2014","journal-title":"J Hepatol"},{"key":"R36-6-20241212","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: A multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R38-6-20241212","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature"},{"key":"R39-6-20241212","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/MEG.0b013e328362797b","article-title":"Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons a-2a and a-2b, plus ribavirin","volume":"25","author":"Dogan","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R40-6-20241212","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2008.04.015","article-title":"Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response","volume":"135","author":"Ferenci","year":"2008","journal-title":"Gastroenterology"},{"key":"R41-6-20241212","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1086\/592579","article-title":"Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: A multicenter, randomized controlled trial","volume":"47","author":"Liu","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R42-6-20241212","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"van der Meer","year":"2012","journal-title":"JAMA"},{"key":"R43-6-20241212","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"Martin","year":"2013","journal-title":"Hepatology"}],"container-title":["Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/02223309-201746010-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T18:59:07Z","timestamp":1751482747000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijmr.org.in\/newer-direct-acting-antivirals-for-hepatitis-c-virus-infection-perspectives-for-india\/"}},"subtitle":["Perspectives for India"],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmr.ijmr_679_15","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}